Exact Sciences initiated with bullish view at Wolfe Research, here’s why

As previously reported, Wolfe Research initiated coverage of Exact Sciences with an Outperform rating and $95 price target, citing its combination of “unmatched regulatory, reimbursement, scientific, and commercial prowess.” The firm, which sees a “clear path to upside relative to current 2024 Street expectations,” argues that pullbacks on competitive headlines typically represent an opportunity.